TPV/eGFP-treated subjects demonstrated a marginal regression in tumor volume compared to vehicle controls, again supporting the role CCL-2 and IL-2 play in the negative regulation of BxPC-3 human PDAC xenografts in our immunocompromised test system. This evidence concerns the gene IL2 and neoplasm.